Courtesy of Benzinga.
ekmira Pharmaceuticals Corporation (Nasdaq: TKMR) disclosed that Alnylam Pharmaceuticals, Inc. filed a patent infringement lawsuit against Tekmira in the U.S. District Court of the District of Massachusetts. Isis Pharmaceuticals, Inc. is named as a co-plaintiff in the suit.
The context for this infringement suit has arisen out of the ongoing litigation between Tekmira and Alnylam Pharmaceuticals, Inc. and AlCana Technologies, Inc. (“AlCana”) currently filed in Massachusetts Superior Court.
“Tekmira is confident that we have access to all the intellectual property we require for the development of our own products and for work with pharmaceutical partners,” said Dr. Mark J. Murray, Tekmira’s President and CEO.
As reported earlier, a firm trial date of October 30, 2012 has been set for the ongoing litigation against Alnylam Pharmaceuticals, Inc. and AlCana Technologies, Inc. in Massachusetts Superior Court.
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.
